Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Heron Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Heron Therapeutics, Inc.’s stock price such as:

• Heron Therapeutics, Inc.’s current stock price and volume
• Why Heron Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for HRTX from analysts
• HRTX’s stock price momentum as measured by its relative strength

About Heron Therapeutics, Inc. (HRTX)

Before we jump into Heron Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

Want to learn more about Heron Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Heron Therapeutics, Inc..

Heron Therapeutics, Inc.’s Stock Price as of Market Close

As of February 26, 2026, 10:46 AM, CST, Heron Therapeutics, Inc.’s stock price was $1.213.

Heron Therapeutics, Inc. is up 12.31% from its previous closing price of $1.080.

During the last market session, Heron Therapeutics, Inc.’s stock traded between $1.190 and $1.330. Currently, there are approximately 170.35 million shares outstanding for Heron Therapeutics, Inc..

Heron Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Heron Therapeutics, Inc. Stock Price History

Heron Therapeutics, Inc.’s (HRTX) price is currently down 8.11% so far this month.

During the month of February, Heron Therapeutics, Inc.’s stock price has reached a high of $1.420 and a low of $1.050.

Over the last year, Heron Therapeutics, Inc. has hit prices as high as $2.680 and as low as $1.000. Year to date, Heron Therapeutics, Inc.’s stock is down 6.7%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Heron Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 25, 2026, there was 1 analyst who downgraded Heron Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Heron Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Heron Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Heron Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Heron Therapeutics, Inc. (HRTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Heron Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 25, 2026, Heron Therapeutics, Inc. has a weighted four-quarter relative price strength of -11.30%, which translates to a Momentum Score of 19 and is considered to be Very Weak.

Want to learn more about how Heron Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Heron Therapeutics, Inc. Stock Price: Bottom Line

As of February 26, 2026, Heron Therapeutics, Inc.’s stock price is $1.213, which is up 12.31% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Heron Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.